Worried About Muscle Loss and Reduced Basal Metabolic Rate From GLP-1 Obesity Drugs Like Mounjaro and Wegovy? The Herbal Principle Behind Metabolic Maintenance

1. The Appetite-Suppressing Mechanism of GLP-1 Class Pharmaceuticals and the Biochemical Origins of Rebound Weight Gain After Discontinuation

GLP-1 receptor agonists, represented by semaglutide, tirzepatide, and liraglutide, act directly on the appetite regulation center within the hypothalamus, amplifying satiety signals and delaying gastric emptying speed to induce powerful restriction of caloric intake. While this pharmacological mechanism enables significant short-term weight reduction, the issue lies in the fact that this weight loss process is not selectively confined to fat mass reduction alone.

Under a state of drug-induced appetite suppression, overall food intake itself decreases rapidly, which can result in a concurrent deficiency in essential amino acids and protein intake necessary for muscle protein synthesis. This may lead to a reduction in the activation of the mTOR (mammalian Target of Rapamycin) pathway, a key signaling pathway that regulates muscle protein synthesis within skeletal muscle cells, ultimately raising the possibility of a metabolic imbalance where muscle protein catabolism exceeds synthesis.

This phenomenon, where lean body mass—particularly skeletal muscle mass—decreases disproportionately alongside fat mass, is explained through the pathophysiological concept known as Sarcopenic Obesity. Since skeletal muscle is a metabolically active tissue that accounts for a substantial portion of the body's Basal Metabolic Rate (BMR), a reduction in muscle mass is inevitably linked to a decrease in resting energy expenditure. A body with a lowered basal metabolic rate falls into a metabolically vulnerable state where it expends less energy than before, even when consuming the same caloric intake; this has become a subject of academic interest as it forms the physiological groundwork for a susceptibility to rapid weight regain, or the rebound phenomenon, upon appetite recovery after drug discontinuation.

Therefore, weight loss strategies utilizing GLP-1 class medications require an approach that considers qualitative changes in body composition—specifically, the ratio between fat mass and lean body mass—rather than simply targeting numerical changes on the scale. Without a concurrent strategy that selectively reduces fat mass while maximally preserving muscle mass, pharmacological monotherapy may reveal limitations in terms of sustainable weight management following the conclusion of treatment.

2. BodyallFit Herbal Metabolism Enhancement Mechanism for Basal Metabolic Rate (BMR) Maintenance and Sarcopenia Prevention

From the perspective of Korean medicine, obesity is not interpreted as a simple state of caloric excess, but rather as a pathological state where the transportive-transformative function of the Spleen and Stomach declines, preventing the essence of food and water from converting into a form usable by the body, resulting in stagnation in the form of Phlegm-Fluid Retention or Dampness. From this perspective, the therapeutic strategy of Spleen-Qi Tonification (Bohgi-Geonbi) fundamentally improves the digestive and absorptive function of the Spleen and Stomach, with the core principle being the enhancement of the bioavailability of ingested nutrients, particularly protein.

Unlike the method by which GLP-1 class drugs act directly on the hypothalamus to induce rapid and forceful appetite suppression, Spleen-Qi Tonification-based herbal formulations take an approach that supports the body in more effectively utilizing necessary nutrients by gradually improving the absorption efficiency of the digestive system. This orientation induces natural dietary regulation without abrupt nutritional deficiency, and the theoretical improvement in protein utilization efficiency may contribute to establishing a metabolic environment favorable for muscle mass preservation by increasing the availability of amino acids required for muscle protein synthesis.

The trend of maintaining Basal Metabolic Rate (BMR) and preventing sarcopenia observed in Bodyall Korean Medicine Clinic's accumulated metabolic correction herbal medicine clinical experience forms a point of academic contrast with the biochemical mechanism demonstrated in the cited study by Wilding, et al. (2021)^[1], in which lean body mass was shown to decrease significantly upon administration of a GLP-1 analogue, thereby supporting the theoretical necessity of a muscle mass preservation approach through supporting digestive absorption efficiency. Furthermore, regarding fat metabolism, specific herbal components known to promote thermogenesis via sympathetic nervous system activation and to facilitate the activation of lipolysis enzymes within adipocytes theoretically support metabolic correction directed toward selectively reducing pure body fat mass without loss of muscle mass.

3. Analysis of Academic Clinical Literature on GLP-1-Induced Sarcopenic Obesity and Korean Medicine Spleen-Qi Tonification Treatment

Academic verification regarding the impact of GLP-1 class obesity treatment agents on body composition is being conducted concretely through sub-studies of large-scale clinical trials. According to the body composition sub-analysis results of the STEP 1 study, which verified the effects of semaglutide, total lean body mass measured via Dual-Energy X-ray Absorptiometry (DEXA) decreased by approximately 9.7% from baseline during the 68-week administration period. This result serves as empirical data supporting the fact that GLP-1 receptor agonist-class drugs actually entail muscle mass loss, including skeletal muscle, in addition to fat mass reduction^[1].

These findings can be interpreted as clinical evidence consistent with the mechanistic hypothesis that when reduced protein intake due to drug-induced appetite suppression combines with attenuated mTOR-mediated muscle protein synthesis signaling, muscle loss may be intensified, and the resulting decline in basal metabolic rate may render patients vulnerable to weight regain after treatment discontinuation.

Meanwhile, a similar tendency was confirmed in the body composition sub-analysis of the SURMOUNT-1 study targeting tirzepatide, a dual agonist that simultaneously stimulates both GLP-1 and GIP receptors. In this study, approximately 25% of the total body weight lost, as quantified via Dual-Energy X-ray Absorptiometry, was found to originate from lean body mass, including muscle, which provides additional empirical evidence for the sarcopenic obesity mechanism^[2].

Both studies demonstrate that GLP-1 class drugs, as well as GLP-1/GIP dual agonist-class drugs, may commonly involve a significant decrease not only in adipose tissue but also in muscle mass, a metabolically active tissue, suggesting that when protein intake deficiency and mTOR-mediated muscle protein synthesis signal reduction occur concurrently under drug-induced appetite suppression, this may lead to a decline in basal metabolic rate. This physiological limitation of pharmacological monotherapy provides an academic rationale for the need to integrally consider Spleen-Qi Tonification-based herbal medicine treatment, which promotes muscle mass preservation through supporting digestive absorption efficiency and protein utilization, alongside a physician-led 1:1 behavior modification protocol that includes resistance-based activity guidance.

4. The Metabolic Correction Process of the BodyallFit Weight Loss Program (Metabolic Correction Protocol)

The BodyallFit Weight Loss Program (Metabolic Correction Protocol) is a metabolic correction protocol integrally designed with herbal prescriptions based on the Spleen-Qi Tonification principle and physician-led 1:1 behavior modification therapy, aimed at supplementing the physiological limitations of the rapid appetite suppression method inherent in GLP-1 class drugs. The core of this program lies not simply in accelerating the rate of weight loss, but in a body composition-centered approach that simultaneously pursues the two goals of fat mass reduction and muscle mass preservation.

Specifically, the close management system in which the Chief Director periodically monitors the patient's progress and provides detailed feedback on dietary composition and activity patterns is designed to concurrently manage two axes that are difficult to address through medication alone: supporting muscle protein synthesis signals and habituating resistance-based activity. This integrated approach aims for a sustainable body composition management direction where the basal metabolic rate does not decline rapidly even after the conclusion of treatment, by complementarily combining the powerful initial weight loss effect of GLP-1 class pharmaceuticals with the herbal medicine's mechanism of supporting digestive absorption efficiency and metabolic preservation.

As such, the BodyallFit Weight Loss Program (Metabolic Correction Protocol) can be reviewed as a metabolic preservation-oriented approach for patients who are already taking or considering taking GLP-1 class obesity drugs such as Mounjaro and Wegovy, offering comprehensive management of metabolic health from the perspective of preventing muscle loss and maintaining basal metabolic rate beyond simple weight reduction.